Immune Checkpoint Inhibitors (ICIs) Landscape
Focus - Small Cell Lung Cancer Indication
SCLC is an unforgiving, highly aggressive variant of lung cancer. It accounts for approximately 15% of lung cancer cases globally and is also a major cause of cancer-related deaths. Chemotherapy has been the mainstay in SCLC management. While the response rate to chemotherapy is high, notably, almost all patients relapse after a few months (PFS is typically 4.0 - 5.5 months).
Immunotherapy, which changed the treatment paradigm in Melanoma and NSCLC, has shown only modest benefits in SCLC patients. The latest positive result in the first line was reported from the IMpower 133 trial in which the addition of atezolizumab to chemotherapy resulted in 2 months of overall survival benefit over chemotherapy alone (12.3 months vs 10.3 months) in extensive-stage SCLC patients. These results were the first such improvement reported in about 30 years. Based on these results, FDA approved atezolizumab + chemotherapy for first-line treatment.
We had three specific objectives
We analyzed 104 relevant clinical trials
And identified 28 PD-1/PD-L1 inhibitors
21 PD-1 Inhibitors 1 Bi-specific PD-1/PD-L1 inhibitor 06 PD-L1 Inhibitors
More than 80% of trials involve PD-1 or PD-L1 inhibitors
Bringing everything together
The initial gains observed with ICIs need to be actively followed up by novel combination strategies. While many of the trials are investigating general combinations, there are also several trials that are probing novel combinations (+vaccine, +autologous cell therapy, and others).
1. If you are viewing this webpage on mobile, please use Landscape mode for a better visual and reading experience.
2. For the full report, write to us at firstname.lastname@example.org.